Sign in
4

Changes in Ownership

Fulcrum Therapeutics, Inc. Filed Acc 0000899243-22-013881

Director sold 94,251 shares at an average $24.16 ($2,276,684)

  • Director acquired 94,251 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I
Gould Robert J Director 2022-04-01 Option exercise +34,464 $7.84 $270,198 541,094 D
Gould Robert J Director 2022-04-01 Sale −34,464 $24.03 $828,160 506,630 D
Gould Robert J Director 2022-04-04 Option exercise +7,235 $7.84 $56,722 513,865 D
Gould Robert J Director 2022-04-04 Sale −7,235 $24.02 $173,749 506,630 D
Gould Robert J Director 2022-04-05 Option exercise +52,552 $7.84 $412,008 559,182 D
Gould Robert J Director 2022-04-05 Sale −52,552 $24.26 $1,274,775 506,630 D
Derivatives
Gould Robert J Director 2022-04-01 Option exercise · Stock Option (right to buy) −34,464 289,998 D
Gould Robert J Director 2022-04-04 Option exercise · Stock Option (right to buy) −7,235 282,763 D
Gould Robert J Director 2022-04-05 Option exercise · Stock Option (right to buy) −52,552 230,211 D
Open-market sales · 94,251 sh · avg $24.16 · $2,276,684
Loading xslF345X03/doc4.xml…